Shots:

• The ongoing P-III maintenance study evaluates the efficacy and safety of upadacitinib (15/30 mg- qd) vs PBO in patients with a mod. to sev. UC
• The study met the 1EPs & 2 EPs i.e @ 52 wks.- patients achieved clinical remission (per Adapted Mayo Score) (42%/ 52% vs 12%)- endoscopic improvement (49%/62% vs 14%)- HEMI (35%/ 49% vs 12%)- corticosteroid-free remission (57%/68% vs 22%) & clinical response @8wks. induction treatment
• The safety results were consistent with the previous P-III induction studies in UC- no new safety risks were observed. The results from the P-III maintenance study will be presented & submitted for publication in a peer-reviewed journal

  Ref: Abbvie | Image: abbvie